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ABSTRACT
The interaction between genetic factors, blood glucose and hypertension plays a role in 
the onset of diabetic kidney disease (DKD) in type II diabetes mellitus (T2DM). Genetic 
variation of TGF-ß1 is associated with renal complication in T2DM with varying results 
between ethnicities. The Jambi Malay ethnic, which is the majority ethnic in Jambi 
Province, is an area that reports an increased prevalence of T2DM with DKD as the most 
frequent microvascular complications. In addition, previous study reported controlling 
blood glucose not associated with DKD indicating genetic may have play a role in DKD 
in this population. Studies related to genetic variation and decreased kidney function 
in T2DM patients has never been performed in this ethnic group. This study aimed to 
investigate the role of TGF-ß genetic variation as risk factor for decreased renal function 
in T2DM patients from Jambi Malay ethnicity. We conducted a cross sectional study 
involving 70 patients with T2DM. The inclusion criteria for renal complication based 
on a decrease in the glomerular filtration rate (GFR) of less than 60 mL/min/1.73. The 
genotyping method used was amplification refractory mutation system polymerase 
chain reaction (ARMS-PCR) for TGF-β1 rs1800470 T/C. Bivariate and multivariate analysis 
was performed to analyze phenotype and genotype association. The result of bivariate 
analysis showed T2DM patients with genotype CT (p:0.006; OR:0.125; 95% CI:0.027-0.575) 
and CC (p:0.007; OR:0.104; 95% CI:0.020-0.546) or C allele carrier (p:0.003; OR:0.117; 
95% CI:0.027-0.500) had lower risk for decreased renal function than TT genotype. 
Multivariate analysis that included blood pressure and age variables showed the same 
finding for CT (p:0.007; OR:0.086; 95% CI:0.014-0.508) and CC genotype (p:0.022; OR:0.115; 
95% CI:0.018-0.731). It is concluded from this study that T2DM patients with genotype 
CT, CC and carrier allele C have a lower risk for suffering kidney complications than 
genotype TT.
ABSTRAK
Interaksi antara faktor genetik, kadar gula darah dan hipertensi berperan dalam 
timbulnya komplikasi  penyakit ginjal diabetes (PGD) pada pasien diabetes melitus tipe 
II (DMT2). Variasi genetik TGF-ß1 berhubungan dengan komplikasi ginjal pada pasien 
DMT2 dengan hasil yang bervariasi antar etnik. Etnik Melayu Jambi yang merupakan 
etnik mayoritas di Provinsi Jambi, merupakan daerah yang melaporkan peningkatan 
prevalensi DMT2 dan penyakit ginjal diabetes sebagai komplikasi mikrovaskular 
terbanyak. Penelitian sebelumnya juga melaporkan kontrol gula darah  tidak berkaitan 
dengan kejadian PGD. Hal ini mengindikasikan kemungkinan peran variasi genetik pada 
kejadian PGD dipopulasi ini. Penelitian terkait variasi genetik dan penurunan fungsi 
ginjal pada pasien DMT2 belum pernah dilakukan pada etnis ini. Tujuan penelitian ini 
adalah mengkaji hubungan antara variasi genetik TGF-ß1 dengan kejadian PGD pada 
etnis Melayu Jambi.  Penelitian  potong lintang ini melibatkan 70 pasien DMT2. Kriteria 
inklusi penurunan fungsi ginjal berdasarkan penurunan laju filtrasi glomerulus (GFR) 
kurang dari 60 mL/min/1.73. Metode genotiping yang digunakan adalah Amplification 
Refractory Mutation System Polymerase Chain Reaction (ARMS-PCR) untuk TGF-β1 
rs1800470 T/C. Analisis bivariat dan multivariat dilakukan untuk menganalisis 
hubungan fenotipe dan genotipe. Hasil analisis bivariat menunjukkan subjek DMT2 
dengan genotipe CT (nilai p:0,006; OR:0,125; 95% CI:0,027-0,575) dan CC (nilai p:0,007; 
OR:0,104; 95% CI:0,020-0,546) memiliki risiko yang lebih rendah dalam penurunan 
fungsi ginjal dibandingkan genotipe TT. Analisis multivariat model regresi logistik yang 
memasukkan variabel tekanan darah dan usia juga menunjukkan hasil yang sama 
untuk CT (nilai p:0,007; OR:0,086; 95% CI:0,014-0,508) and CC (nilai p:0,022; OR:0,115; 
95% CI:0,018-0,731). Dapat disimpulkan bahwa subjek DMT2 dengan genotipe CT, CC dan 
karier alel C dari TGF-β1 rs1800470 memiliki risiko lebih rendah menderita komplikasi 
ginjal dibandingkan genotipe TT. 
J Med Sci, Volume 53, Number 4, 2021 October:
INTRODUCTION
The increasing prevalence of type 
II diabetes mellitus (T2DM) worldwide 
including in Indonesia leads to 
increasing diabetic kidney diseases 
(DKD). Diabetic kidney diseases caused 
decline renal function, which burden 
patient quality of life and health cost.1,2 
Based on Indonesian National Health 
Surveillance, Jambi Province is one 
of regions in Indonesia that reported 
the phenomenon. The prevalence of 
T2DM had increased from 1.1 % in 
2013 to 1.4 % in 2018.3 Diabetic kidney 
diseases prevalence is higher than other 
microvascular complication in this 
region.4
In many studies across the world 
population, controlling blood glucose 
level and blood pressure as modifiable 
risk of DKD does not always prevent 
the onset of decreased renal function in 
T2DM patients.5 The study in Malay Jambi 
ethnic reported similar result.6 The new 
biomarker and genetic variant may play 
role in this event. Genetic factors are risk 
factors that cannot be modified, but early 
screening of these factors can provide 
information about the pathophysiology 
of DKD and promises hope for better 
treatment and prognosis.5,7
Hyperglycemia in DM induced 
oxidative  stress and chronic 
inflammation which induced 
transforming  growth factor beta (TGF-ß) 
expression. The TGF-ß1 cause deposition 
of extra-cellular matrix leads to renal 
fibrosis and decreased renal function. 
Previous study reported that TGF-ß1 level 
is the marker for degree of progressive 
decreased in renal function in T2DM.8-10
Genetic variation of TGF-ß1 
rs1800470 T/C is missense mutation. The 
mutation cause changes of amino acid, 
in which Leucine substitute to Proline in 
codon 10 of TGF-ß1 gene. The substitution 
associated with alteration of TGF-ß1 level 
or function.11,12 In line to the functional 
study, this genetic variant associated 
with risk of chronic kidney diseases 
(CKD) and end stage renal disease (ESRD) 
for all causes include microvascular 
complication of T2DM. This is unique 
because the study reported difference in 
allele risk for CKD and ESRD, which may 
be influenced by ethnic factors. 13-19
Previous study reported higher 
prevalence of DKD than other 
microvascular complication in T2DM, 
blood glucose level as modifiable risk 
factor cannot always be used as clinical 
marker to prevent the progressive 
decreased renal function in DKD among 
Jambi Malay population. It may indicate 
that the genetic variants have play role 
as risk for that event in this population. 
Furthermore, to the best of our knowledge 
association of TGF-ß genetic variation 
rs1800470 T/C with decreased renal 
function in T2DM patient has never been 
conducted in Jambi Malay population. 
This study aimed to investigate the role 
of genetic variation in the incidents 
of decreased renal function in T2DM 
patients in Jambi Malay population.
MATERIALS AND METHODS
Study design
This study was approved by the 
Ethic Research Committee, the Faculty 
of Medicine and Health Sciences, 
Universitas Jambi with number 2163/
UN21.8/PG/2020. This research was 
a cross sectional study involving 70 
patients with T2DM. The inclusion 
criteria were patients who had suffered 
from T2DM for at least 5 years, age 35-
67 years old and Jambi Malay ethnic. All 
subjects signed an informed consent. 
The exclusion criteria were patient 
who had suffered from urinary tract 
infection based on clinical examination 
and routine urine analysis, had a history 
of other renal diseases, pregnant women 
and immunocompromised patients.
Patients with T2DM were diagnosed 
based on plasma fasting blood glucose 
>126 mg/dL and or 2 h post prandial 
plasma glucose > 200 mg/dL as listed 
in medical records. We also measured 
serum creatinine and blood pressure in 
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all subjects. All subjects signed informed 
consent forms after receiving detailed 
explanation about the study objectives 
and design. The research protocol was 
arranged based on the declaration of 
Helsinki.
Blood pressure and laboratory 
measurement
Systolic and diastolic blood pressure 
was measured using a calibrated 
sphygmomanometer. The measurement 
was taken twice in a sitting position 
after the patients rested for 5 min. 
Subjects with a systolic blood pressure 
≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg were classified as 
uncontrolled hypertension.20 
Blood  peripheral  samples  (5 mL) 
were obtained from the antecubital 
vein after eight to 10 h of fasting. This 
blood sample was used to measure 
serum creatinine  levels  and  fasting 
blood  glucose plasma levels. The 2 
h post prandial plasma glucose was 
measured 2 h after glucose loading (75 
g glucose loading). The plasma glucose 
level was measured with glucose 
oxidase peroxidase amino-antipyrin 
(GOD-PAP) methods performed by 
PRODIA laboratories. Subjects with 
plasma fasting glucose >130 mg/dL were 
classified as uncontrolled plasma fasting 
glucose. Subjects with 2 h post prandial 
plasma fasting glucose ≥ 180 mg/dL were 
classified as uncontrolled plasma 2 h 
post prandial plasma fasting glucose.20
The decreased of renal function was 
determined based on GFR less than 60 
mL/min/1.73. The GFR was calculated 
based on chronic kidney disease 
epidemiology collaboration (CKD-EPI) 
equation, based on estimated creatinine 
serum, gender equation coefficient and 
age. Serum creatinine levels ware also 
measured with enzymatic colorimetric 
Jaffe methods performed by PRODIA 
laboratories.
Genotyping and data analysis
Deoxyribonucleic acid (DNA) was 
extracted from peripheral vein buffy 
coat using commercial DNA blood 
extraction kit from Macrogen®. Quality 
and quantity of DNA were measured 
using nanodrop with nanodrop index at 
least ~1.8. Genotyping was performed by 
two step tetra Amplification refractory 
mutation system-polymerase chain 
reaction (ARMS-PCR) which showed 
general product and allele specific 
product. Primer design was adapted 
from Perrey et al.21   Primer sequences 
and its product are showed in TABLE 1.
The PCR mixture were 5 µM generic 
primer; 5 µM C allele or T allele specific 
primer; 5 µM for each internal control 
primer P53F (Genetica Sciences®); 
12,5 µL PCR master mix (Go taq green, 
Promega®); nuclease free water 8, µL; 
DNA template 1 µL.  The thermocycler 
(Biorad®) condition was 95 °C for 7 min 
as initial denaturation and 1 min as 
denaturation; 60 °C for 1 min as annealing; 
72 °C as extension for 1 min and 7 min 
as final extension. The PCR product then 
visualized with 2.5% agarose gel for 45 
min with 100 mV.
TABLE 1. Primer and the product size
Primer Fragment
Generic primer (sense/reverse primer) 5´-TCCGTGGGATACTGAGACAC-3´
C allele specific primer (antisense/
forward primer)
5´-GCAGCGGTAGCAGCAGCG-3´ 241 bp
T allele specific primer (antisense) 5´- AGCAGCGGTAGCAGCAGCA-3´ 241 bp
Internal control primer 1 (P53F) 5´-TGCCCTGTGCAGCTGTGGGTTGATT- 3´
Internal control primer 2 (P53R) 5´-GCCCCAGCTGCTCACCATCGCTATC- 3´
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In silico analysis was performed to 
measured primer sequences and the size 
of its product. The genotyping method 
was optimized based on our laboratory 
resources in which optimal fragment 
visualization. Quality measurement of 
PCR reaction was determined based on 
internal primer band appearance, nihil 
band appearance in control negative 
(no DNA template was added in control 
negative PCR mixture) and certain 
fragment size of PCR product for allele. 
As much 10% of sample was performed 
twice for genotyping to ensure the result 
and all the second genotyping process 
showed consistency with the first one.
Bivariate analysis test was performed 
for baseline subject characteristic and 
association between genotype and 
decreased renal function. Moreover, 
multivariate analysis was performed 
to analyzed blood pressure and blood 
glucose as covariable of genotype.
RESULT
Baseline subject characteristic
A total of 70 patients who met 
research criteria were involved in this 
study. Grouping of subjects based on GFR 
(cut off point for GFR) was less than 60 
mL/min/1.73. Subjects characteristic are 
showed in TABLE 2. Patients T2DM with 
decreased renal function were older 
and had lower GFR than patients T2DM 
without decreased renal function.









Age (years) 54.22±5.55 49.39±7.91 0.012*
Glomerular filtration rate (mL/min) 36.33±14.56 94.67±19.58 <0.001*
Gender
•	Male 10 18 0.528
•	Female 12 30
Blood pressure (mmHg)
•	Uncontrolled blood pressure 10 6 0.002*
•	Controlled blood pressure 12 42
Fasting plasma glucose (mg/dL)
•	Uncontrolled FPG 13 26 0.700
•	Controlled FPG 9 22
2 h PP plasma glucose (mg/dL)
•	Uncontrolled 2 hours PP plasma 
glucose
19 41 0.916
•	Controlled 2  PP plasma glucose 3 7
Numeric scale data were analyzed using t-test; All the numeric data were normally 
distributed; Chi-square test was performed for categoric scale; *Statistically significant, 
p < 0.05; DM refers to diabetes mellitus; FPG refers to fasting plasma glucose; PP refers to 
post prandial.
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We found a higher frequency 
of controlled blood pressure was in 
T2DM without a statistically significant 
decrease in renal function. The frequency 
of uncontrolled fasting and blood 
glucose 2 h post prandial was higher in 
DM without decrease in renal function, 
but the difference was not statistically 
significant (TABLE 2).
Genotype distribution
The PCR product visualization is 
showed in FIGURE 1. The T and C size of 
allele fragment is 241 bp, the difference 
based on specific primer for each allele. 
Internal control for PCR reaction is the 
appearance of p53 fragment product 
(180 bp).
FIGURE 1. Two step electrophoresis of ARMS-PCR TGF-ß 
rs1800470. The size of allele C and T fragment were 
241 bp, the lowest fragment was internal control 
p53 (180 bp). Sample number 33, 35, 36, 38 had 
heterozygote CT. Sample number 34 had homozy-
gote CC and sample number 37 had homozygote TT. 
Negative control (NC) before sample 33 showed no 
band appearance.




2 (DF) p MAF
CC 23 24
CT 36 34 0.25 0.62 0.41
TT 11 12
X2value with degree of freedom (DF)=1; MAF=minor allele frequency
Genotype distributions in our 
population are showed in TABLE 
3. Genotype of TT was reported as 
polymorphic genotype in the population. 
Percentage of minor allele in our 
population was 41%, T allele was the 
minor allele. The proportion of genotype 
frequency in our studies were not 
deviated from Hardy Weinberg equation, 
p> 0.05 (TABLE 3).
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Association of genotype with 
decreased renal function
TABLE 4 shows the result of bivariate 
analysis. The frequency of subjects who 
had CC and C allele were lower in T2DM 
with decreased renal function group. 
The frequency of subject who had CT, 
CCCT genotype were higher in T2DM 
without decreased renal function group. 
This difference is statistically significant.
Odds ratio value showed CT, CC, 
CCCT genotype and C allele had lower 
susceptibility for suffering decreased 
renal function. This association was 
statistically significant (TABLE 4).









function (n=48) p OR (95% CI)
Additive model
TT 8 (36.4) 3 (6.3) ref
CT 9 (40.9) 27 (56.3) 0.006b*
0.125
(0.027-0.575)




CTTT 17 (77.3) 30 (62.5) ref
CC 5 (22.7) 18 (37.5) 0.172a
0.490
(0.154-1.557)
TT 8 (36.4) 3 (6.3) ref




T 25 (56.8) 33 (34.4) ref
C 19 (43.2) 63 (65.6) 0.012a*
0.398
(0.192-0.826)
aChi square; bFisher exact test was performed; *Statistically significant, p < 0.05; 
OR refers to odds ratio; CI refers to confident interval; Ref refers to reference 
genotype.
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TABLE 5. Multivariate analysis of association between genotype and 
decreased renal function
Variable B SE Adjusted p Adjusted OR 95% CI
Additive model
TT ref
CT -2.458 0.908 0.007 0.086 0.014-0.508
CC -2.163 0.944 0.022 0.115 0.018-0.731
Uncontrolled 
blood pressure 1.557 0.691 0.024 4.744 1.223-18.396
Age 0.122 0.057 0.034 1.129 1.009-1.264
Recessive model
TT ref
CCCT -2.335 0.848 0.006 0.097 0.018-0.510
Uncontrolled 
blood pressure 1.518 0.681 0.026 4.565 1.203-17.327
Age 0.118 0.056 0.036 1.126 1.008-1.258
Hosmer and Lemeshow test was performed to analyzed the good fitness in both 
model; p for all model was > 0.05; B refers to logistic regression model coefficient; 
SE refers to standard error; OR refers to odds ratio with 95% Confident Interval (CI); 
ref refers to reference genotype.
Multivariate analysis with logistic 
regression model showed consistent 
trends with bivariate analysis. The 
subject with CT, CC, and CCCT had lower 
susceptibility for suffering decreased 
renal function than TT genotype. The 
genetic OR as a protective factor in 
multivariate analysis was lower than 
OR in bivariate analysis when adjusted 
for uncontrolled blood pressure and 
increasing age. The association was 
statistically significant. In addition, 
uncontrolled blood pressure and 
increasing age also increase The 
susceptibility to decreased renal function 
in T2DM (TABLE 5).
DISCUSSION
The age, duration of suffering T2DM, 
blood pressure, and blood glucose level 
are classic risk factors that play a role 
in decreased renal function in T2DM 
patients. Controlled blood pressure and 
controlled blood glucose level do not 
always prevent this complication Genetic 
factors thought to be involved.2,5,22 Our 
research reported the older age, blood 
pressure, and TGF-ß genetic variant were 
associated with decreased renal function 
in T2DM.
Uncontrolled blood pressure in 
T2DM patients increases glomeruli 
capillary pressure, mechanical stress 
of mesangial cell, podocytes, and RAAS 
activation. It induces a concerted release 
of proinflammatory and profibrotic 
cytokine including TGF-ß, which 
accelerates the progression of decreased 
renal function.5 Higher frequency of 
uncontrolled blood glucose level in 
T2DM patients without decreased renal 
function may indicate that there are 
other factors that played role in T2DM 
with decreased renal function. One 
of those factors is the involvement of 
genetic factors, which was also found 
in this study. The TGF-ß genetic variant 
rs1800479 is one of the risk factors for 
decreased renal function in T2DM.
In our population, the polymorphic 
genotype showed opposite than the 
association of phenotype-genotype 
studies.13-19 We reported TT genotype 
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and T allele as polymorphic form in this 
study. This difference may be influenced 
by ethnicity and the difference of subject 
criteria for recruitment. Although our 
research sample was small in number, 
the observed value of our genotype 
did not deviate from Hardy-Weinberg 
equation. We believe that our genotyping 
method has a very small bias in addition 
to the Hardy-Weinberg law assumptions 
for population genetic.
Genotype and phenotype study in 
our population reported the statistical 
significance of CT, CC genotype, and 
C allele carrier of TGF-ß rs1800470 
as protective risk for decreased 
renal function both in bivariate and 
multivariate analysis. Previous study 
reported this genetic variant associated 
with CKD and ESRD for all caused 
include T2DM renal complication. The 
difference allele risk was found between 
those studies. Studies in Spanish and 
German population report that the TT 
genotype was more susceptible to ESRD 
than CC and TC genotype for all caused 
than another genotype. Same linkage 
trends was also found in ESRD caused by 
microvascular complication of T2DM. 13,14 
Our study also reported similar genotype 
risk.
In contrast to the result of several 
studies in in Egypt, India, and Mexican 
which reported that C allele and CC 
genotype increased risk of suffering 
diabetic nephropathy with or without 
ESRD in T2DM patient.15-17 One meta-
analysis of 9 case-control studies 
reported the CC genotype of this genetic 
variant associated with higher risk of 
CKD in Asian.18 Another recent meta-
analysis study in Chinese population 
reported CC genotype increased risk of 
suffering T2DM renal complication by 
1.14 -1.67 than other genotype.19
The TGF-β1 rs1800470 T/C genetic 
variant is an exon variant that plays a 
role in protein coding. This missense 
mutation causes the amino acid to code 
Leucin to proline, different amino acid 
changing polarity of the protein and 
influence the trafficking or exportingthe 
intracellular protein.23 Previous study 
also reported the difference genotype 
associated with different TGF-β1 level.11,12 
TGF-β1 level associated with T2DM renal 
complication through its role as inducer 
of excess extracellular matrix cause 
glomerulosclerosis and lead to decreased 
renal function.8-10 This may explain 
contribution of this genetic variant as 
risk for decreased renal function in 
T2DM.
Genotyping methods used for 
TGF-β1 rs1800470 T/C genetic variant 
was two steps ARMS PCR. This technique 
allows fast, reliable and low cost for 
SNP genotyping than PCR-RFLP or HRM-
PCR.24,25 this is the kind of a proper 
genotyping technique that can be used 
in limited laboratory resources. This 
method uses generic primer and specific 
allele primer. The quality control of PCR 
reaction is based on visualization of 
PCR product of p53 gene (one of house-
keeping gene) and negative control for 
contamination exclusion, then 10% of 
sample genotyping twice. The primer 
was adapted from Perrey et al.21 then in 
silico analysis was performed to measure 
the primer sequences and PCR product 
size. PCR condition optimization was 
based on our laboratory resources.
Limitation of this study was 
single center pilot study and single 
genetic variant measurement which 
influenced decreased renal function 
of T2DM patient. Further research 
with larger sample, multicenter, more 
comprehensive genetic and nongenetic 
analysis are needed to determine this 
genetic variant as genetic screening 
for decreased renal function in T2DM 
patient. Genetic screening serves as a 
promising step that can promote the 
better treatment and prognosis.
CONCLUSION
We report that T2DM-affected 
subjects who carry the TC, CC, or C 
allele of TGF-β1 rs1800470 have a lower 
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susceptibility to suffering decreased 
renal function. Further research with 
larger samples and comprehensive 
analysis of genetic and non-genetic factor 
are needed to strengthen the role of this 
genetic variant as risk for decreased 
renal function in T2DM.
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